Last reviewed · How we verify
Neurology Center of New England P.C. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Abobotulinumtoxin A | Abobotulinumtoxin A | phase 3 | Botulinum toxin | SNAP-25 (synaptosome-associated protein of 25 kDa) | Neurology |
Therapeutic area mix
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie · 1 shared drug class
- Allergan · 1 shared drug class
- Amir Moradi MD, MBA · 1 shared drug class
- Beth Israel Deaconess Medical Center · 1 shared drug class
- Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
- EuBiologics Co.,Ltd · 1 shared drug class
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 shared drug class
- ASIS Corporation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Neurology Center of New England P.C.:
- Neurology Center of New England P.C. pipeline updates — RSS
- Neurology Center of New England P.C. pipeline updates — Atom
- Neurology Center of New England P.C. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Neurology Center of New England P.C. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurology-center-of-new-england-p-c. Accessed 2026-05-18.